AI
ALXN

Analytic Investors’s Alexion Pharmaceuticals ALXN Stock Holding History

Analytic Investors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-5,940
Closed -$985K – 639
2014
Q3 		$985K Buy
5,940
+215
+4% +$35.3K 0.01% 369
2014
Q2 		$895K Buy
+5,725
New +$904K 0.01% 331

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Analytic Investors's ALXN Position: Q4 2014 in Review

Analytic Investors sold out of Alexion Pharmaceuticals (ALXN) in Q4 2014, closing a stake of 5,940 shares — an estimated $985K sold.

Analytic Investors first reported a position in ALXN in Q2 2014 and held it in 2 quarters. The position peaked at $985K in Q3 2014. 579 funds tracked by Wall St. Rank hold ALXN as of Q4 2014.

  • Analytic Investors reported no remaining Alexion Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Analytic Investors sold 5,940 Alexion Pharmaceuticals shares in Q4 2014, an estimated $985K.
  • Analytic Investors first reported a position in Alexion Pharmaceuticals in Q2 2014 and held it in 2 quarters.
  • Analytic Investors's Alexion Pharmaceuticals position peaked at $985K in Q3 2014.
  • 579 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2014.

Based on Analytic Investors's 13F filing for Q4 2014, filed 9 Feb 2015.